Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01780506 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
A Phase 3 study of HIV Infections and HIV, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 872
- Enrollment target
- 20
- Study locations
NCT01780506 is a Phase 3 study of HIV Infections and HIV that has completed, run by Gilead Sciences. The registered enrollment target is 872 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (96% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT01780506, a Phase 3 study of HIV Infections and HIV, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 872 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
Conditions Studied
Interventions
- DRUG E/C/F/TAF
- DRUG E/C/F/TDF
- DRUG E/C/F/TDF Placebo
- DRUG E/C/F/TAF Placebo
Study Locations (20)
California
- Kaiser Permanente Los Angeles - Los Angeles
- University of California, Los Angeles - Los Angeles
- Peter J. Ruane, MD, Inc. - Los Angeles
- Anthony Mills MD Inc - Los Angeles
- East Bay AIDS Center - Oakland
- Kaiser Permanente - Sacramento - Sacramento
- La Playa Medical Group and Clinical Research - San Diego
- University of California, San Diego - San Diego
- Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance
Florida
- Gary Richmond, MD, PA, Inc. - Fort Lauderdale
- Midway Immunology & Research Center, LLC - Ft. Pierce
- The Kinder Medical Group - Miami
- AIDS Healthcare Foundation - Miami Beach
District of Columbia
- Dupont Circle Physicians Group, P.C. - Washington D.C.
- Whitman Walker Clinic - Washington D.C.
- Capital Medical Associates, P.C. - Washington D.C.
Alabama
- The University of Alabama at Birmingham - Birmingham
Arizona
- Spectrum Medical Group - Phoenix
Colorado
- Apex Research, LLC - Denver
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 872 participants |
| Start Date | 2012-12-26 |
| Est. Completion | 2017-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01780506
The ClinicalTrials.gov registry entry for NCT01780506 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 872 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (96% higher). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which E/C/F/TAF is the first listed.
NCT01780506 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01780506 about?
NCT01780506 is a clinical study titled "Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults". The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatme...
What is the current status of trial NCT01780506?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 872 participants. The study started on 2012-12-26. Estimated completion is 2017-09-06.
What conditions does trial NCT01780506 study?
This clinical trial studies the following conditions: HIV Infections, HIV.
What interventions are being tested in trial NCT01780506?
The interventions under investigation include: E/C/F/TAF (DRUG), E/C/F/TDF (DRUG), E/C/F/TDF Placebo (DRUG), E/C/F/TAF Placebo (DRUG).
Who is sponsoring clinical trial NCT01780506?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01780506 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.